Gemcitabine plus nab-paclitaxel vs. FOLFIRINOX for patients with advanced pancreatic cancer

Cancer Chemotherapy and Pharmacology
Junko TaharaKatsutoshi Tokushige

Abstract

New chemotherapies have become available for the treatment of advanced pancreatic cancer and have led to changes in its standard treatments. Since pancreatic cancer is becoming more common as a result of population aging, there is a need for diversification of chemotherapy. Between March 2014 and April 2017, FOLFIRINOX (FFX) or gemcitabine plus nab-paclitaxel (G-nab) was used as first-line therapy to treat 27 patients with locally advanced and metastatic pancreatic cancer at our hospital. In this study, we retrospectively evaluated their clinical characteristics, survival outcomes and adverse events. Twelve of the 27 patients were treated with FFX, and the other 15 patients were treated with G-nab. The disease control rate was 86.7% in the G-nab group and 75% in the FFX group. Median OS time was 8.9 months in the FFX group and 11.8 months in the G-nab group. The 1-year survival rate was 46.6% in the G-nab group and 16.6% in the FFX group. The second-line treatment rate was 40% in the G-nab group and 66.7% in the FFX group. The grade 3-4 neutropenia rate was 20% in the G-nab group and 25% in the FFX group. No patients developed febrile neutropenia, or severe nausea, diarrhea, or anorexia. The peripheral sensory neuropathy rate w...Continue Reading

References

Jun 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H A BurrisD D Von Hoff
May 13, 2011·The New England Journal of Medicine·Thierry ConroyUNKNOWN PRODIGE Intergroup
Oct 5, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel D Von HoffManuel Hidalgo
Oct 18, 2013·The New England Journal of Medicine·Daniel D Von HoffMarkus F Renschler
Feb 6, 2015·CA: a Cancer Journal for Clinicians·Lindsey A TorreAhmedin Jemal
Dec 29, 2016·World Journal of Gastroenterology : WJG·Marwan GhosnJoseph Kattan
Oct 21, 2017·Clinical Journal of Gastroenterology·Minami HashimotoHiromasa Ohira

❮ Previous
Next ❯

Citations

Jun 1, 2019·Expert Review of Anticancer Therapy·Veethika Pandey, Peter Storz
Jun 4, 2019·The New England Journal of Medicine·Talia GolanHedy L Kindler
Sep 22, 2020·World Journal of Clinical Cases·Sung Yong HanHyung-Il Seo
Jun 18, 2019·Therapeutic Advances in Medical Oncology·Elena Gabriela ChioreanSalah-Eddin Al-Batran
Jun 23, 2021·World Journal of Surgical Oncology·Beilei ZhangYunbao Xu
Jul 23, 2021·Journal of the National Comprehensive Cancer Network : JNCCN·Héctor G van den BoornHanneke W M van Laarhoven

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anorexia Nervosa

Anorexia nervosa (AN) is a psychiatric condition characterized by severe weight loss and secondary problems associated with malnutrition. Here is the latest research on AN.

Related Papers

Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen
O Strobel, M W Büchler
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
Juliette ViaudAstrid Lièvre
© 2022 Meta ULC. All rights reserved